CHB 111

Drug Profile

CHB 111

Alternative Names: CHB-111; HepaVaxx B

Latest Information Update: 05 Jan 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ViRexx Medical Corp
  • Developer Paladin Labs
  • Class Hepatitis B vaccines; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Hepatitis B

Most Recent Events

  • 23 Dec 2008 ViRexx Medical Corp has been acquired and merged into Paladin Labs
  • 25 Jul 2007 Suspended - Phase-I for Hepatitis B in Canada (SC)
  • 14 May 2007 ViRexx has completed a phase I safety trial of CHB 111 in healthy volunteers in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top